Abstract
Genome.One and OneOme said they will partner to provide insights into individuals’ genetic risk of disease and pharmacogenomic responses through Australia’s first whole genome and health assessment service. The service will combine genome sequencing provided by Australian-based Genome.One and pharmacogenomic testing using the RightMed test of U.S.-based OneOme.
RightMed analyzes an individual’s DNA to identify how that may affect his or her response to certain medications, such as predicting adverse drug reactions and drug effectiveness. RightMed was co-developed and exclusively licensed from the Mayo Clinic, with the goal of bringing pharmacogenomics into routine clinical care.
“Information from our RightMed test can help healthcare providers make prescriptions more personal,” OneOme CEO Paul Owen said. “We believe in bringing the benefits of pharmacogenomics to everyone, and we’re thrilled to be partnering with Genome.One to make our service available to more people than ever before.”
Results from the genome sequencing and pharmacogenomic testing will be incorporated into a comprehensive health assessment to be offered with Darlinghurst, Australia-based Life First. The assessment is intended to provide additional health and wellbeing information for a more comprehensive picture of an individual’s health.
catenarymedia / Getty Images
